Conmed Corp reports results for the quarter ended June 30 - Earnings Summary
Conmed Corp reports results for the quarter ended June 30 - Earnings Summary
Conmed Corp CNMD.N reported quarterly adjusted earnings of $1.38 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.15. The mean expectation of seven analysts for the quarter was for earnings of $1.11 per share. Wall Street expected results to range from $1.07 to $1.12 per share.
Revenue rose 0.3% to $343.49 million from a year ago; analysts expected $337.56 million.
Conmed Corp's reported EPS for the quarter was 77 cents.
The company reported quarterly net income of $23.07 million.
Conmed Corp shares had risen by 35.2% this quarter and gained 9.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.4% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Conmed Corp is $39.00, about 10.8% below its last closing price of $43.21
This summary was machine generated from LSEG data July 29 at 11:23 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 1.11 | 1.38 | Beat |
Mar. 31 2026 | 0.82 | 0.89 | Beat |
Dec. 31 2025 | 1.32 | 1.43 | Beat |
Sep. 30 2025 | 1.05 | 1.08 | Beat |
Recent news on Conmed
See all newsU.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Conmed Corp reports results for the quarter ended June 30 - Earnings Summary
Conmed Q2 sales, adjusted profit beat on organinc platform growth
Brief: Conmed Q2 Adjusted EPS USD 1.38 Vs. IBES Estimate USD 1.11
Brief: Conmed Is Said To Weigh Sale After Takeover Interest- Bloomberg News